Janssen Research & Development Demonstrates Continued Commitment To Combating Hepatitis C In European Patients With Data Presented At Viral Hepatitis Congress

FRANKFURT, Germany--(BUSINESS WIRE)--Janssen R&D Ireland (Janssen) today announced the presentation of additional data for the NS3/4A protease inhibitor OLYSIO® (simeprevir) at the Viral Hepatitis Congress (VHC) in Frankfurt, Germany. The data includes new analysis of a European and Israeli Hepatitis C (HCV) patient subset within the previously presented ATTAIN Phase 3 study. Additional data presented investigates treatment considerations for a broad range of patient populations including the renal function of those treated with simeprevir as well as the prevalence of the polymorphism of Q80k in European genotype 1 (GT1) patients.

The new analysis of the Phase 3 ATTAIN study (n=763), showed sustained virological response at 12 weeks (SVR12) to be similar in European and Israeli patients compared to previous analysis of the overall patient population (GT1, null and prior responder patients).1 Importantly these results have shown that Week 4 response rates are a good predictor of SVR12, showing that the majority of patients treated with simeprevir and pegIFN/ RBV with HCV RNA <25 IU/ml at Week 4, were likely to achieve SVR by week 12.2

Help employers find you! Check out all the jobs and post your resume.

Back to news